Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

MIC1/GDF15 as a Bone Metastatic Disease Biomarker

J. Windrichova, R. Fuchsova, R. Kucera, O. Topolcan, O. Fiala, J. Finek, D. Slipkova,

. 2017 ; 37 (3) : 1501-1505.

Language English Country Greece

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc17023203

AIM: The aim of the study was to evaluate MIC1/GDF15 as a biomarker in the monitoring of bone metastases occurrence. PATIENTS AND METHODS: The assessed group included patients diagnosed with: prostate cancer, breast cancer, lung cancer and colorectal cancer. Patients were divided into two groups based on the scintigraphy of the occurrence of bone metastases. Group 0 contained 55 patients without bone metastases, that served as the control group. Group 1 contained 75 patients with bone metastases. RESULTS: Higher levels (p<0.0001) of MIC1/GDF15 were found in group 1 (with bone metastases) compared to the group 0. Receiver operating characteristic (ROC) analysis showed an area under the curve (AUC) 0.87. At the point of 90% specificity we found a 65% sensitivity and cut-off value of 1.48 ng/ml. CONCLUSION: Circulating MIC1/GDF15 is a powerful biomarker for bone metastatic disease but insufficient sensitivity calls for further studies incorporating combinations with other novel or routine markers.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17023203
003      
CZ-PrNML
005      
20170828131009.0
007      
ta
008      
170720s2017 gr f 000 0|eng||
009      
AR
024    7_
$a 10.21873/anticanres.11477 $2 doi
035    __
$a (PubMed)28314325
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Windrichova, Jindra $u Department of Immunochemistry, Medical School and Teaching Hospital in Pilsen, Charles University in Prague, Prague, Czech Republic.
245    10
$a MIC1/GDF15 as a Bone Metastatic Disease Biomarker / $c J. Windrichova, R. Fuchsova, R. Kucera, O. Topolcan, O. Fiala, J. Finek, D. Slipkova,
520    9_
$a AIM: The aim of the study was to evaluate MIC1/GDF15 as a biomarker in the monitoring of bone metastases occurrence. PATIENTS AND METHODS: The assessed group included patients diagnosed with: prostate cancer, breast cancer, lung cancer and colorectal cancer. Patients were divided into two groups based on the scintigraphy of the occurrence of bone metastases. Group 0 contained 55 patients without bone metastases, that served as the control group. Group 1 contained 75 patients with bone metastases. RESULTS: Higher levels (p<0.0001) of MIC1/GDF15 were found in group 1 (with bone metastases) compared to the group 0. Receiver operating characteristic (ROC) analysis showed an area under the curve (AUC) 0.87. At the point of 90% specificity we found a 65% sensitivity and cut-off value of 1.48 ng/ml. CONCLUSION: Circulating MIC1/GDF15 is a powerful biomarker for bone metastatic disease but insufficient sensitivity calls for further studies incorporating combinations with other novel or routine markers.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a plocha pod křivkou $7 D019540
650    _2
$a nádorové biomarkery $x metabolismus $7 D014408
650    _2
$a nádory kostí $x metabolismus $x sekundární $7 D001859
650    _2
$a nádory prsu $x metabolismus $x patologie $7 D001943
650    _2
$a kohortové studie $7 D015331
650    _2
$a kolorektální nádory $x metabolismus $x patologie $7 D015179
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a regulace genové exprese u nádorů $7 D015972
650    _2
$a růstový diferenciační faktor 15 $x metabolismus $7 D055436
650    _2
$a lidé $7 D006801
650    _2
$a nádory plic $x metabolismus $x patologie $7 D008175
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a metastázy nádorů $7 D009362
650    _2
$a nádory prostaty $x metabolismus $x patologie $7 D011471
650    _2
$a ROC křivka $7 D012372
650    _2
$a radioisotopová scintigrafie $7 D011877
650    _2
$a senzitivita a specificita $7 D012680
655    _2
$a časopisecké články $7 D016428
700    1_
$a Fuchsova, Radka $u Department of Immunochemistry, Medical School and Teaching Hospital in Pilsen, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Kucera, Radek $u Department of Immunochemistry, Medical School and Teaching Hospital in Pilsen, Charles University in Prague, Prague, Czech Republic kucerar@fnplzen.cz.
700    1_
$a Topolcan, Ondrej $u Department of Immunochemistry, Medical School and Teaching Hospital in Pilsen, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Fiala, Ondrej $u Department of Oncology and Radiotherapy, Medical School and Teaching Hospital in Pilsen, Charles University in Prague, Prague, Czech Republic. Biomedical Center, Faculty of Medicine in Pilsen, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Finek, Jindrich $u Department of Oncology and Radiotherapy, Medical School and Teaching Hospital in Pilsen, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Slipkova, Dagmar $u Department of Immunochemistry, Medical School and Teaching Hospital in Pilsen, Charles University in Prague, Prague, Czech Republic.
773    0_
$w MED00000478 $t Anticancer research $x 1791-7530 $g Roč. 37, č. 3 (2017), s. 1501-1505
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28314325 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170720 $b ABA008
991    __
$a 20170828131555 $b ABA008
999    __
$a ok $b bmc $g 1238884 $s 984116
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 37 $c 3 $d 1501-1505 $i 1791-7530 $m Anticancer research $n Anticancer Res $x MED00000478
LZP    __
$a Pubmed-20170720

Find record

Citation metrics

Logged in users only

Archiving options